The Australian share market has seen a flurry of activity from leading brokers this past week, resulting in a raft of new recommendations and analyses. For investors keeping a close eye on the ASX, several “buy” ratings have emerged that warrant a closer look. Here’s a breakdown of three ASX-listed companies that brokers believe are currently in the “buy zone.”
Breville Group Ltd (ASX: BRG): A Strong Outlook for Appliance Innovation
Macquarie analysts have reaffirmed their “outperform” rating on Breville Group Ltd, a prominent appliance manufacturer. While they have slightly adjusted their price target to $37.10, the overall sentiment remains positive. Macquarie’s assessment is underpinned by favourable industry data, suggesting Breville is not only performing well but potentially outshining its competitors.
The broker points to several key drivers behind this optimistic outlook:
- Robust Coffee Business Growth: Breville’s established presence and innovation in the coffee machine segment continue to be a significant contributor to its success.
- New Product Introductions: The company’s consistent pipeline of innovative new products is resonating well with consumers and expanding its market reach.
- Expansion into New Markets: Strategic entry and growth in new geographical markets are further bolstering Breville’s revenue streams.
Macquarie forecasts that these factors position Breville for sustained annual growth exceeding 10% through to the 2028 financial year. At the close of the past trading week, Breville Group shares were trading at $26.28.
Cochlear Ltd (ASX: COH): Hearing Solutions Poised for Recovery
UBS has maintained its “buy” rating on Cochlear Ltd, a global leader in implantable hearing solutions, with a price target of $302.00. The investment bank views recent dips in Cochlear’s share price as an attractive entry point for investors. This optimism is largely fuelled by the anticipated impact of Cochlear’s next-generation cochlear implant platform, Nexa.
UBS believes that Nexa is set to drive a significant earnings recovery for the company. The broker highlights Cochlear’s strong competitive position, noting that with limited rivals, the company is well-equipped to capture an increasing share of the market. While acknowledging concerns surrounding gene therapies, UBS suggests that these are unlikely to affect Cochlear’s near-term performance. The company’s shares closed the week at $170.23.
Liontown Ltd (ASX: LTR): A Lithium Play with Upside Potential
In another note from UBS, analysts have reiterated their “buy” rating on Liontown Ltd, a significant lithium miner, setting a price target of $2.20. UBS’s positive stance on the lithium sector is particularly relevant at this juncture, with the broker suggesting that now could be an opportune moment for investors to consider exposure to the industry.
The potential for another lithium price upcycle is a key factor in UBS’s bullish outlook. The broker speculates that rising oil prices and ongoing supply disruptions, exacerbated by geopolitical events in the Middle East, could indirectly benefit the lithium market. The reasoning is that increased fuel costs might accelerate the adoption of electric vehicles, thereby driving higher demand for lithium used in batteries. UBS anticipates that the price of spodumene, a key lithium-bearing mineral, could potentially reach US$4,000 per tonne by the end of the year. Liontown’s share price concluded the week at $1.76.
These three companies represent diverse sectors within the Australian market, each presenting unique opportunities for investors based on broker insights and market trends.















































